drugset / Trial / NCT01209325

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

NCT01209325

NaSingle-groupOpen-labelPrevention

Summary

RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection. PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.

Timeline

Start
2011-06-28
Primary completion
2017-12-12
Completion
2017-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil Vaccine